Federal health regulators have rejected an application filed by Acadia Pharmaceuticals to expand the use of its blockbuster antipsychotic drug, Nuplazid, highlighting concerns that the medication may not be effective among certain subgroups of dementia patients.…
Nuplazid is a recently introduced medication that is used to treat hallucinations caused by Parkinson’s disease. However, side effects of Nuplazid have already been linked to an alarming number of adverse events and patient deaths, leading to serious questions about whether benefits outweigh the potential health risks and whether a Nuplazid recall may be necessary. …
An ISMP report questions the FDA conclusions that there are no new safety signals with the Parkinson’s disease psychosis drug, Nuplazid.…
The FDA has launched a new safety review of the Parkinson’s disease drug Nuplazid, FDA Commissioner Scott Gottlieb told Congress last week.…
More than 700 deaths have been linked to Nuplazid side effects, raising concerns about the safety of the Parkinson’s disease drug.…
The side effects of Nuplazid may increase the risk of hallucinations in some Parkinson’s disease patients, according to the findings of a new report.…
